As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
BiTEs Bring New Side Effects To Solid Tumor Setting
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
